Kipu Quantum Expands Quantum Computing Capabilities with Strategic Acquisition of PlanQK Platform

In a significant move poised to redefine the landscape of quantum computing accessibility, Kipu Quantum GmbH has announced the acquisition of PlanQK, the pioneering German quantum computing platform developed by Anaqor AG. This strategic integration brings together two leaders in the field, aiming to accelerate the development and deployment of industrially relevant quantum solutions worldwide….

Read More

Hebbia Raises $130 Million to Supercharge Enterprise Knowledge Retrieval with AI

Big bucks for brains! New York AI startup Hebbia just landed a cool $130 million in Series B funding, a war chest to revolutionize how businesses find information. Tech titans Andreessen Horowitz and Index Ventures led the round, with heavy hitters like Peter Thiel and Google’s venture arm joining the party. This investment spree signifies…

Read More

FreeBnk Raises $3 Million to Expand Innovative Crypto Investment Platform

In a stride forward for the fintech industry, Lithuanian startup FreeBnk has secured $3 million in combined equity and token funding to bolster its cutting-edge cryptocurrency investment app. This funding round was led by prominent investors including Founderheads, ChaiTech Ventures, LVT Capital, and Lavender Capital, signifying robust confidence in FreeBnk’s vision and capabilities. Founded with…

Read More

German Startup planqc Secures €50 Million to Revolutionize Quantum Computing

In a significant development for the future of computing, German quantum computing company planqc has secured €50 million in a Series A funding round. This substantial investment, led by the European Family Office CATRON Holding and the DeepTech & Climate Fonds (DTCF), propels planqc to the forefront of the global race to develop fault-tolerant quantum…

Read More

Zhiyi Biotech Reports Successful Phase I Results for SK10 in Chemotherapy-induced Diarrhea Treatment

Zhiyi Biotech, a pioneering clinical-stage biotech specializing in live biotherapeutic products (LBPs), has achieved significant milestones with its latest clinical trial results for SK10. The Phase I study, conducted in the United States, has demonstrated promising outcomes in the treatment of chemotherapy-induced diarrhea (CID) using SK10, an innovative heat-killed Bacteroides fragilis product. The randomized, double-blind,…

Read More

QED Protocol Secures $6 Million Funding Round to Revolutionize Bitcoin-powered Web3 Applications

QED Protocol, a pioneering force in the realm of Web3 development leveraging Bitcoin’s capabilities, has announced a successful $6 million funding round led by Blockchain Capital. This investment is set to propel QED’s groundbreaking technology, which promises to redefine the landscape of smart contracts, layer-two solutions, and various Web3 applications. QED Protocol stands at the…

Read More

Nature Takes Center Stage: Natcap Secures $10 Million to Integrate Nature into Business Decisions

In a significant win for environmental awareness, Natcap, a pioneering nature intelligence company, has secured $10 million in an oversubscribed Series A funding round. This impressive feat, achieved amidst a challenging global fundraising environment, underscores the growing recognition of nature’s critical role in business strategy. The funding round, led by prominent figures like André Hoffmann…

Read More

Iktos Expands AI-Driven Drug Discovery Capabilities with Acquisition of Synsight

Iktos, a pioneering leader in AI and Robotics for drug design, has announced its acquisition of Synsight, a renowned French biotech company specializing in AI-driven drug discovery targeting protein-protein (PPI) and RNA-protein (RPI) interactions. This strategic merger bolsters Iktos’ comprehensive AI-based drug discovery platform, integrating Synsight’s advanced technology to enhance biological testing capabilities crucial for…

Read More

Myricx Bio Secures £90 Million Series A Funding to Revolutionize Cancer Treatment with Novel NMTi-ADC Therapeutics

A new wave of hope is washing over the oncology field with Myricx Bio’s impressive £90 million ($114 million) Series A funding. This UK biotech company, unlike its peers, isn’t taking an incremental step forward. Instead, they’re wielding a whole new weapon in the fight against cancer: N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugates (ADCs). The significance…

Read More